WRN helicase is a synthetic lethal target in microsatellite unstable cancers.

Journal Article (Journal Article)

Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics1. DNA repair processes represent attractive synthetic lethal targets, because many cancers exhibit an impairment of a DNA repair pathway, which can lead to dependence on specific repair proteins2. The success of poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors in cancers with deficiencies in homologous recombination highlights the potential of this approach3. Hypothesizing that other DNA repair defects would give rise to synthetic lethal relationships, we queried dependencies in cancers with microsatellite instability (MSI), which results from deficient DNA mismatch repair. Here we analysed data from large-scale silencing screens using CRISPR-Cas9-mediated knockout and RNA interference, and found that the RecQ DNA helicase WRN was selectively essential in MSI models in vitro and in vivo, yet dispensable in models of cancers that are microsatellite stable. Depletion of WRN induced double-stranded DNA breaks and promoted apoptosis and cell cycle arrest selectively in MSI models. MSI cancer models required the helicase activity of WRN, but not its exonuclease activity. These findings show that WRN is a synthetic lethal vulnerability and promising drug target for MSI cancers.

Full Text

Duke Authors

Cited Authors

  • Chan, EM; Shibue, T; McFarland, JM; Gaeta, B; Ghandi, M; Dumont, N; Gonzalez, A; McPartlan, JS; Li, T; Zhang, Y; Bin Liu, J; Lazaro, J-B; Gu, P; Piett, CG; Apffel, A; Ali, SO; Deasy, R; Keskula, P; Ng, RWS; Roberts, EA; Reznichenko, E; Leung, L; Alimova, M; Schenone, M; Islam, M; Maruvka, YE; Liu, Y; Roper, J; Raghavan, S; Giannakis, M; Tseng, Y-Y; Nagel, ZD; D'Andrea, A; Root, DE; Boehm, JS; Getz, G; Chang, S; Golub, TR; Tsherniak, A; Vazquez, F; Bass, AJ

Published Date

  • April 2019

Published In

Volume / Issue

  • 568 / 7753

Start / End Page

  • 551 - 556

PubMed ID

  • 30971823

Pubmed Central ID

  • PMC6580861

Electronic International Standard Serial Number (EISSN)

  • 1476-4687

Digital Object Identifier (DOI)

  • 10.1038/s41586-019-1102-x


  • eng

Conference Location

  • England